Malecare Prostate Cancer Support Group

survival benefit

On The Horizon – MDV3100 in Men With Advanced Prostate Cancer Study Will Be Stopped Early and MDV3100 Offered to All Participants

It was announced yesterday that the Independent Data Monitoring Committee (IDMC) has informed the the pharmaceuticals, Medivation and Astellas of positive results from a planned interim analysis of the Phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. The monitoring committee found that MDV3100, the first androgen receptor [...]

By |2017-10-19T10:51:56-04:00November 4th, 2011|Advanced Prostate Cancer, Chemo Therapy Failure, Clinical Trials, Clinical Trials, Drugs & Treatments, MDV3100, On The Horizon, Uncategorized|1 Comment
Read More

Study Finds that Degarelix is Superior to Leuprolide

According to findings from a long term study, men with prostate cancer (PCa) who are treated with degarelix (a newly approved gonadotropin-releasing hormone receptor (GnRH) blocker) have a lower risk of PSA failure or death compared with those treated with leuprolide. […]

By |2017-10-19T10:52:24-04:00June 24th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Firmagon (degarelix), Hormone Therapy, Research, Uncategorized, Understanding APC|1 Comment
Read More

Surgery Improves Survival Rates for Men with Advanced Prostate Cancer

Researchers from the Mayo Clinic recently announced results at the American Urological Association (AUA) Annual Meeting from a long-term study that indicates that surgery can improve life expectancy for men with advanced prostate cancer. Their study shows that 80% of men who have advanced prostate cancer and still choose to have surgery survive for at [...]

By |2011-05-22T12:01:53-04:00May 22nd, 2011|Advanced Prostate Cancer, AUA, Drugs & Treatments, General Information, Research, Uncategorized, Understanding APC|1 Comment
Read More

Study Shows that Six Months of Neoadjuvant ADT Significantly Reduces Mortality in Locally Advanced Prostate Cancer

Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men with locally advanced prostate cancer. […]

By |2011-03-28T13:49:05-04:00March 28th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, Research, Uncategorized, Understanding APC, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments
Read More
Go to Top